Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...
As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...
After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...
With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...
In this episode of Denatured, BioSpace's Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER about his thoughts on the future of cell and gene therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback